Compare Cassava Sciences Inc (FLNA) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Microchip Technology Inc. — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Microchip Technology Inc. trades at $81.9 (market cap $46.84B). The key difference: Microchip Technology Inc. is far larger — about 881.4× Cassava Sciences Inc's market cap, and Microchip Technology Inc. pays a 2.11% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MCHP | |
|---|---|---|
Market Cap | $53.14M | $46.84B |
Sector | Health | Technology |
52-Week High | $4.64 | $102.97 |
52-Week Low | $1.09 | $49.02 |
Enterprise Value | -$33.43M | $52.13B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Microchip Technology (MCHP) trades at $82.18, down 5.66% today, with a bearish technical signal but strong analyst consensus. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.57 surpassing the $0.505 estimate. The company maintains a solid gross margin of 57.73% but reported a net loss in 2025. Positive news highlights growth in AI, industrial IoT, and aerospace sectors, with new product launches like the VectorBlox 3.0 SDK and space-grade clock generators.
MCHP shows potential from AI and aerospace demand, with a $113.33 average price target implying 38% upside. However, high valuations (P/E 392.09, P/S 9.98) and recent net income challenges pose risks. Investors should weigh robust cash flow and market positioning against debt levels and cyclical semiconductor pressures. The stock's outlook hinges on execution in recovering end-markets and sustaining earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
